Matthew Reynolds-Tejeda
Senior Associate Scientist, Nanoparticle Process Development Strand Therapeutics
After being exposed to how important delivery vehicles are for effective therapeutics, I worked on formulation & process development of LNPs for vaccine use between 2022-2023. After joining Strand Therapeutics, I have been primarily working in LNP process development where I have scaled programs from early-stage R&D to pre-clinical. I also have worked with our manufacturing team to engage in tech transfer activities.
Seminars
Tuesday 7th April 2026
Optimizing TFF by Incorporating Membrane Screening & In-Process Analytics to Enhance Buffer Exchange & Concentration
3:30 pm
- Tackling key challenges in TFF loading to guide hollow fiber vs flat sheet selection
- Exploring screening strategies for membrane selection to ensure product quality during concentration and solvent removal
- Walking over flux excursions and evaluation of membrane modalities for TFF of LNPs
